335, 335J,

Potential health effects

ADDITIONAL HEALTH EFFECTS Before using read the Fluoropolymers Safe Handling Guide published by The Society of the Plastics Industry and "Dispersion Properties and Processing Techniques", Bulletin X-50G (E-55514-2). Skin and eye irritation from contact with the liquid is the primary hazard from fluoropolymer dispersions as shipped. Inhalation of fumes from overheating or burning the resin may cause "polymer fume fever" (see HUMAN HEALTH EFFECTS below). High temperatures such as sintering operations may release vapors. These vapors may condense as a solid or as a liquid solution in the oven, exhaust duct or stack, or on other cool surfaces. Do not breath off-gases and avoid skin contact with condensate when cleaning the oven, stack, etc. TFE-PPVE COPOLYMER Inhalation of PFA dust may cause generalized irritation of the nose, throat and lungs with cough, difficulty breathing or shortness of breath. Heating PFA above 300 degrees C may liberate a fine particulate fume. Inhalation may produce polymer fume fever, a temporary flu-like condition with fever, chills, nausea, shortness of breath, chest tightness, muscle or joint ache, and sometimes cough and elevated white blood cell count. The symptoms are often delayed 4 to 24 hours after exposure. These signs are generally temporary, lasting 24-48 hours and resolve without further complications. However, some individuals with repeated episodes of polymer fume fever have reported persistent pulmonary effects. Protection against polymer fume fever should also provide protection against any potential chronic effects. Exposure to decomposition products from PFA heated above 400 degrees C may cause pulmonary inflammation, hemorrhage or edema. These more serious consequences of exposure may occur from extreme thermal decomposition of PFA which can liberate fume particles, and toxic gases (carbonyl fluoride, hydrogen fluoride, and other fluorinated gases) especially under conditions of poor ventilation and/or confined spaces. These decomposition products may initially produce chest tightness or pain, chills, fever, nausea, with shortness of breath, cough, wheezing and progression into pulmonary edema. Edema may be delayed in onset and requires medical treatment. In severe cases, if medical intervention is delayed, pulmonary edema may become life threatening. Recovery is generally complete within a few days; in some rare cases, persistent lung function abnormalities have been reported. Continued) Compared to nonsmokers, polymer fume fever symptoms appear to be more prevalent and serious in smokers. Smokers must avoid contamination of tobacco with residual polymer from their hands or from fumes, and should wash their hands before smoking. No skin irritation is expected during routine or occasional handling of PFA. Prolonged skin contact may cause mild skin irritation. Significant skin permeation after contact appears unlikely. There are no reports of human sensitization. If particles of PFA contact the eye mechanical irritation with tearing, pain or blurred vision may result. Individuals with pre-existing diseases of the lungs or cardiovascular system may have increased susceptibility to the reduction in blood oxygen that may develop after excessive exposures to thermal decomposition products. SURFACTANT May irritate skin, eyes, nose and throat. Ingestion may cause upper abdominal pain, "heart burn", nausea, vomiting and diarrhea. AMMONIUM PERFLUOROOCTANOATE This compound is a skin, eye, nose and throat irritant. Skin permeation may occur in toxic amounts. Ingestion may cause gastrointestinal irritation, liver effects and anemia. At combustion temperatures it may form hydrogen fluoride which is lethal at low concentrations. OF OVEREXPOSURE BY Skin contact may initially include: skin irritation with discomfort or rash. Evidence suggests that skin permeation can occur in amounts capable of producing the effects of systemic toxicity. Eye contact may initially include: eye irritation with discomfort, tearing, or blurring of vision. Inhalation may initially include: irritation of the upper respiratory passages, with coughing and discomfort. Ingestion may initially include: gastrointestinal tract irritation; abnormal liver function as detected by laboratory tests; or abnormal blood forming system function with anemia. This compound is absorbed by the body and may be detected in the blood stream following ingestion, inhalation or skin contact. Animal and human experience indicate that this compound has a long half-life in the blood, and may be Continued) detected years after exposure. Individuals with preexisting diseases of the liver, or bone marrow may have increased susceptibility to the toxicity of excessive exposures. Carcinogenicity Information The following components are listed by IARC NTP